The board of directors of Sino Biopharmaceutical Limited announced that "Sofosbuvir Tablets" (Brand name: Suoweidi), a new antiviral drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC, being the second generic drug of its kind that has obtained approval for drug registration in the PRC, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Sofosbuvir is used for the treatment of Chronic Hepatitis C Virus (HCV) infection as it has the characteristic of pan-genotypic efficacy, high clinical recovery rate, easy medication, no significant side effects, low incidence of virus resistance, and high safety and effectiveness on patients with severe liver disease. The introduction of Sofosbuvir makes Hepatitis C become a clinical completely curable disease. Currently, various new domestic and international guidelines have recommended Sofosbuvir as the first- line treatment for Hepatitis C. World Health Organisation set the goal of "eliminating viral hepatitis as a major health threat by 2030". As a core medicine for Hepatitis C, Sofosbuvir is one of the key elements to achieve such goal. The approval of Suoweidi can further relieve the treatment burden of domestic Hepatitis C patients and contribute to the early elimination of Hepatitis C.